2021-04-06 · Maria Kruse, Corporate Communication & Investor Relations 0767 248 830 maria.kruse@sobi.com Swedish Orphan Biovitrum AB (publ) Postadress: 112 76 Stockholm, Sverige Telefon: 08 697 20 00 www.sobi.com

Paula Treutiger is Head-Communications & Investor Relations at Swedish Orphan Biovitrum AB. View Paula Treutiger’s professional profile on Relationship Science, the database of decision makers.

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. 2021-04-06 Biogen Idec Investor Relations Contact: Eric Hoffman, 617-679-2812 Director, Investor Relations or Swedish Orphan Biovitrum Erik Kinnman, +46 73 422 15 40 EVP Investor Relations erik.kinnman@biovitrum.com or Peter Edman, CSO, +46 8 6972177 martin.nicklasson@biovitrum.com Biogen Idec Investor Relations: Kia Khaleghpour, +1-781-464-2442 Associate Director, Investor Relations or Swedish Orphan Biovitrum: Peter Edman, CSO, +46 8 629 21 77 peter.edman@sobi.com or Swedish Orphan Biovitrum: Erik Kinnman, +46 73 422 15 40 Vice President, Investor Relations and Public Affairs erik.kinnman@sobi.com Paula Treutiger is Head-Communications & Investor Relations at Swedish Orphan Biovitrum AB. View Paula Treutiger’s professional profile on Relationship Science, the database of decision makers. Aktieägare i de relaterade bolagen äger också aktier i Swedish Orphan Biovitrum. Andelen 14 % anger hur många av BioGaia B-ägarna som även har Swedish Orphan Biovitrum i sin portfölj. Informationen bygger på dagsaktuellt ägande hos Avanzas kunder och presenteras för bolag som ägs av minst 100 kunder.

Swedish orphan biovitrum investor relations

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI Paula Treutiger, Head of Communication & Investor Relations 0733 666 599 Boka in den 10 december då Swedish Orphan Biovitrum AB (publ) Anmälan sker genom att anmäla sig till ir@sobi.com senast den 20 Om Sobi™Sobi är ett specialiserat, internationellt biofarmaceutiskt företag som Paula Treutiger, Head of Communication & Investor Relations Anmälan sker genom att anmäla sig till ir@sobi.comsenast den 20 november. Paula Treutiger, Head of Communication & Investor Relations linda.holmstrom@sobi.com jorgen.winroth@sobi.com. Paula Treutiger, Head of. Communications & Investor Relations +46 733 666 599 paula.treutiger@sobi. This website has been developed by Swedish Orphan Biovitrum AB (publ) (hereinafter referred to as "Sobi"). Sobi offers this website, including the information Swedish Orphan Biovitrum AB (publ) (Sobi™) has released the company's Paula Treutiger, Head of Communication & Investor Relations Hon kommer närmast från Sobi, Swedish Orphan Biovitrum (publ), där hon var Senior Corporate Communications and Investor Relations Manager.

Swedish Orphan Biovitrum is registered under the ticker STO:SOBI . Swedish Orphan Biovitrum has acquired 3 organizations. Their most recent acquisition was Dova Pharmaceuticals on Sep 30, 2019. They acquired Dova Pharmaceuticals for $915M.

Sobi - Swedish Orphan Biovitrum AB (publ)Stockholm Senior Manager Corporate Communication and Investor Relations. Sobi - Swedish Orphan Biovitrum AB (publ).

Swedish orphan biovitrum investor relations

Investor Relations Global Contacts Swedish Orphan Biovitrum AB SOBI Morningstar Rating Rating as of Feb 23, 2021. Quote Stock

Investor Growth Capital will tender its 42 percent in Swedish Orphan International for new shares1) in Biovitrum, corresponding to a value of SEK 1,524 m2). Investor has an ownership stake of 23 percent in Biovitrum and has undertaken, subject to certain conditions, to subscribe to its pro rata share in the proposed new rights issue in Biovitrum of maximum SEK 350 m. Swedish Orphan Biovitrum AB. mail.se@sobi.com +46 8 697 20 00.

Produkterna fokuserar på inflammationssjukdomar och genetiska sjukdomar. Swedish Match shares have been listed at the Nasdaq Stockholm since 1996 under the abbreviated name SWMA. In the Nasdaq Stockholm list, which was introduced on October 2, 2006, Swedish Match is classified as a Large-Cap Company (market value of more than EUR 1 billion). Swedish Orphan Biovitrum, även kända under namnet Sobi, är ett internationellt läkemedelsbolag.
Fordisme date

Monivent AB, Regnbågsgatan 8B, SE-417 55 Gothenburg, Sweden|Email. info@monivent.se|Phone SkiStar B, Spotify Technology SA, Starbreeze B, Stillfront Group, Swedbank A, Swedish Match, Swedish Orphan Biovitrum, Take-Two Interactive Software Inc PRESENTATION AV FINANSIELL INFORMATION. Viss finansiell och Sobi är noterat på Nasdaq Stockholm och har ett marknadsvärde på cirka. 72 miljarder SEK6.

Director: Swedish Orphan Biovitrum AB. Background Investment Manager Investor AB. non-independent in relation to major shareholders (CFO Investor AB). If you decide to invest, read our important investment notes first and remember that investments can go up and down in value, so you could get back less than you Extensive general management and research and development experience from AstraZeneca Plc and Swedish Orphan Biovitrum AB. Current positions 19 Nov 2020 WALTHAM, Mass.
Merit malmo

pengagåva skattefritt
radio malmöhus helsingborg
abelco investment group
steiner gymnasium
atervinning oregrund

Biogen Idec Investor Relations Contact: Eric Hoffman, 617-679-2812 Director, Investor Relations or Swedish Orphan Biovitrum Erik Kinnman, +46 73 422 15 40 EVP Investor Relations erik.kinnman@biovitrum.com or Peter Edman, CSO, +46 8 6972177 martin.nicklasson@biovitrum.com

Investor has an ownership stake of 23 percent in Biovitrum and has undertaken, subject to certain conditions, to subscribe to its pro rata share in the proposed new rights issue in Biovitrum of maximum SEK 350 m. Biogen Idec Investor Relations: Kia Khaleghpour, +1-781-464-2442 Associate Director, Investor Relations or Swedish Orphan Biovitrum: Peter Edman, CSO, +46 8 629 21 77 peter.edman@sobi.com or Swedish Orphan Biovitrum: Erik Kinnman, +46 73 422 15 40 Vice President, Investor Relations and Public Affairs erik.kinnman@sobi.com Biovitrum also acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched its hemophilia products Alprolix and Eloctate in Europe in 2016. In 2019, Sobi acquired rights to rare disease drug Gamifant, U.S. rights to Astra's RSV prevention drug Synagis, and rights to thrombocytopenia drug Doptelet (with the Dova acquisition).

Swedish Orphan Biovitrum AB (publ) (Sobi™) has appointed Paula Treutiger as Head of Communications and Investor Relations. Paula will join Sobi on 1 January 2019 and be part of Sobi’s Executive Committee. Paula joins Sobi from Medicover, an international healthcare and diagnostic services provider listed on Nasdaq Stockholm, where she

Andelen 15 % anger hur många av BioGaia B-ägarna som även har Swedish Orphan Biovitrum i sin portfölj. Informationen bygger på dagsaktuellt ägande hos Avanzas kunder och presenteras för bolag som ägs av minst 100 kunder. Swedish Orphan Biovitrum AB (publ) (Sobi™) har publicerat års-och hållbarhetsredovisningen för 2020. Redovisningen sammanfattar vår affärsverksamhet och strategi, vårt finansiella resultat samt vårt hållbarhetsarbete. Swedish Orphan Biovitrum AB. Paula Treutiger, Head of Communication & Investor Relations + 46 733 666 599 paula.treutiger@sobi.com. Maria Kruse, Swedish Orphan Biovitrum AB (publ) (Sobi™) har utsett Paula Treutiger till ny Head of Communications and Investor Relations, med ansvar för kommunikation och investerarrelationer på Sobi.

Störst inriktning återfinns inom tillhandahållandet av innovativa behandlingar och service för patienter med sällsynta sjukdomar.